---
title: "Double the GEM, amplify the power of A-shares"
type: "Topics"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/topics/39564453.md"
description: "$Bosera China GEM Index Daily Leveraged (2X) Product (07234.HK)$ChiNext Index (399006.SZ) The ChiNext board has gained +2.16% year-to-date. Performance overview of the top 20 heavyweight stocks on the Shenzhen Stock Exchange's ChiNext board: Investment involves risks. Past investment performance may not be indicative of future results. Investors should not base their investment decisions solely on the information contained in this material. The above information is for reference only and does not constitute and should not be considered as an offer to subscribe for or sell to anyone. Before making any investment decision, investors should read the relevant fund's prospectus and product key facts statement in detail..."
datetime: "2026-03-27T02:47:15.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39564453.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39564453.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39564453.md)
author: "[博时国际](https://longbridge.com/zh-CN/profiles/16136055.md)"
---

> 支持的语言: [English](https://longbridge.com/en/topics/39564453.md) | [繁體中文](https://longbridge.com/zh-HK/topics/39564453.md)


# Double the GEM, amplify the power of A-shares

[$Bosera China GEM Index Daily Leveraged (2X) Product (07234.HK)](https://longbridge.com/quote/07234.HK)[$GEM Index (399006.SZ)](https://longbridge.com/quote/399006.SZ)The GEM Index has gained +2.16% year-to-date.

Performance table of the top 20 heavyweight stocks on the Shenzhen GEM:

Investment involves risks. Past investment performance is not necessarily indicative of future performance. Investors should not base their investment decisions solely on the information contained herein. The above information is for reference only and does not constitute and should not be regarded as an offer to subscribe for or sell to any person. Before making any investment decision, investors should read the relevant fund's prospectus and product key facts statement in detail, including the product features and risk factors contained therein. Investors should consider whether the product is suitable for them based on their own investment experience, investment objectives, financial situation, and risk tolerance. Seek independent professional advice if necessary. The above information has not been reviewed by the Securities and Futures Commission of Hong Kong.

Issued by: Bosera International. No part of this document or any information contained herein may be photocopied, distributed, or reproduced without the consent of Bosera International.[$Contemporary Amperex Technology (300750.SZ)](https://longbridge.com/quote/300750.SZ)[$East Money Information (300059.SZ)](https://longbridge.com/quote/300059.SZ)[$Inovance Technology (300124.SZ)](https://longbridge.com/quote/300124.SZ)[$Zhongji Innolight (300308.SZ)](https://longbridge.com/quote/300308.SZ)[$Mindray Bio-Medical Electronics (300760.SZ)](https://longbridge.com/quote/300760.SZ)[$Eoptolink Technology (300502.SZ)](https://longbridge.com/quote/300502.SZ)[$Sungrow Power Supply (300274.SZ)](https://longbridge.com/quote/300274.SZ)[$Wens Foodstuff Group (300498.SZ)](https://longbridge.com/quote/300498.SZ)

### 相关股票

- [ChiNext (399006.CN)](https://longbridge.com/zh-CN/quote/399006.CN.md)
- [CATL (03750.HK)](https://longbridge.com/zh-CN/quote/03750.HK.md)
- [CATL (300750.CN)](https://longbridge.com/zh-CN/quote/300750.CN.md)
- [Inovance (300124.CN)](https://longbridge.com/zh-CN/quote/300124.CN.md)
- [XL2 BOS CHINEXT (07234.HK)](https://longbridge.com/zh-CN/quote/07234.HK.md)
- [Zhongji Innolight (300308.CN)](https://longbridge.com/zh-CN/quote/300308.CN.md)
- [Eoptolink (300502.CN)](https://longbridge.com/zh-CN/quote/300502.CN.md)
- [CATL HK SDR 30to1 (HCCD.SG)](https://longbridge.com/zh-CN/quote/HCCD.SG.md)